Holen Sie sich die Stockscreener-App
2.905
1.93%
0.055
Nrx Pharmaceuticals Inc Aktie (NRXP) Neueste Nachrichten
NRX Pharmaceuticals Is Maintained at Buy by Ascendiant Capital - Moomoo
NRx Pharmaceuticals, Inc. (NRXP) stock price, news, quote and history - uk.finance.yahoo.com
Radnor's NRx Pharmaceuticals Lands $11M DARPA Contract to Pair Robotic TMS With Its Depression Drug - BioBuzz
NRx Pharmaceuticals, Inc. (NRXP) Stock Price, News, Quote & History - Yahoo! Finance Canada
DARPA awards NRx USD 11.2m to test NRX-101 with rapid robotic TMS in depression - AllSci
A trial will test a one-day course of brain stimulation and a drug for depression - Stock Titan
NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded - GlobeNewswire
Total common shares outstanding of NRX Pharmaceuticals, Inc. – HAN:B1Q - TradingView
NRX Pharmaceuticals Inc (NRXP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NRXP Should I Buy - Intellectia AI
NRXP Stock Price, Quote & Chart - ChartMill
NRX Pharmaceuticals Inc. R (B1Q.F) Q1 FY2026 earnings call transcript - Yahoo Finance
Why NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Is In Focus Now? - Kalkine Media
NRx Pharmaceuticals, Inc.(NasdaqCM: NRXP) added to S&P Global BMI Index - marketscreener.com
NRx Gets Earlier FDA Goal Date for Ketamine Application - MyChesCo
NRXP Q2 2026 Earnings: EPS Misses Estimate as Company Reports No RevenueNet Income Trends - careplusvn.com
NRx Pharmaceuticals’ ketamine ANDA amendment reclassified - Investing.com India
NRx Pharmaceuticals’ ketamine ANDA amendment reclassified By Investing.com - Investing.com Nigeria
NRX Pharmaceuticals (NRXP) FDA Amendment Reclassification Highli - GuruFocus
GeNeuro, Inc., an NRx Company is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis - marketscreener.com
NRx Pharmaceuticals Announces FDA Reclassification of ANDA Amendment for Preservative-Free Ketamine, Revises GDUFA Goal Date to November 10, 2026 - Quiver Quantitative
NRx Pharmaceuticals, Inc. Reports FDA First Cycle Review Of Preservative-Free Ketamine ANDA With No Drug Related Major Deficiencies And Begins Training And Deployment Of Zeta TMS AI Driven Robotic System In Treatment Of Suicidal Bipolar Depressi - marketscreener.com
Form 8K NRX Pharmaceuticals Inc For: 14 September By Investing.com - Investing.com India
NRx Pharmaceuticals: Promising Ketamine Opportunity In Psychiatry (NASDAQ:NRXP) - Seeking Alpha
GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded - GlobeNewswire
NRXP's KETAFREE shows potential for commercial success pending FDA approval, making NRXP a speculative buy. - Pluang
FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP) - FinancialContent
NRx deploys FDA-cleared robotic TMS system in Florida - grafa.com
NRXP: Preservative-free ketamine and robotic TMS drive innovation, with FDA decision expected soon - TradingView
NRx Pharmaceuticals at Cantor conference: ketamine push gains momentum By Investing.com - Investing.com Canada
NRx Pharmaceuticals Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System - Investing News Network
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System - marketscreener.com
NRx Pharmaceuticals to Present at Three September Investor Conferences - citybiz
NRx Pharmaceuticals to Participate in Upcoming Investor Conferences - Yahoo Finance
NRX Pharmaceuticals Inc. Warrant (NRXPW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
NRX Pharmaceuticals Inc. Warrant (NRXPW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
New to The Street's Prestigious Client NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine - The Ithaca Journal
NRx Pharmaceuticals (NASDAQ:NRXP) Downgraded by Zacks Research to Strong Sell - MarketBeat
H.C. Wainwright reiterates Buy on NRx Pharmaceuticals stock at $45 - Investing.com
H.C. Wainwright reiterates Buy on NRx Pharmaceuticals stock at $45 By Investing.com - Investing.com India
NRx Advances Ketamine Bid After FDA Review Clears Drug - MyChesCo
FDA First Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies Noted for Suicidal Bipolar Depression Treatment from NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - barchart.com
NRX (NRXP) Momentum: Ends Higher by 5.41% at $3.51 for the Current Session; the Current Price Sits Inside the Supplied Technical RangeIV Contraction - Vinanet
NRx cites arbitration in Kadima acquisition dispute - scanx.trade
Nrx Pharmaceuticals Earnings Call Signals Cautious Momentum - TipRanks
NRx Pharmaceuticals Targets 2026 KETAFREE Approval, Advances DARPA-Backed Depression Trial - citybiz
NRx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
BTIG Maintains NRX Pharmaceuticals(NRXP.US) With Buy Rating, Cuts Target Price to $10 - moomoo.com
BTIG Research Reaffirms "Buy" Rating for NRx Pharmaceuticals (NASDAQ:NRXP) - MarketBeat
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update - marketscreener.com
NRX Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
NRX Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
NRx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET - Investing News Network
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):